Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

23AndMe To Go Public At $3.5Bn With Sir Richard Branson-Backed SPAC

Executive Summary

23andMe is teaming up with blank check company VG Acquisition Corp to go public, making the move into personalized health care.

You may also be interested in...



23andMe Acquires Telehealth Company Lemonaid Health For $400M

With the acquisition of Lemonaid Health, at-home genome testing company 23andMe hopes to transform the primary care business with genetics insights.

Digital Health Start-Ups Continue To Be Attractive SPAC Targets

According to Rock Health, 52 health-care focused SPACs are looking for targets. This comes as blank check companies are facing rising scrutiny by regulators.

Exec Chat: Adaptive Biotechnologies Will Use T Cells To Spot Prior Infections, Including COVID-19

Adaptive chief medical officer Lance Baldo talked to Medtech Insight about the company's plans to detect prior infection using T-cells obtained from blood samples.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT143445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel